Syra Health Announces Pricing of $2.1 Million Public Offering
Summary
The potential additional gross proceeds to the Company from the Series Warrants, if fully exercised on a cash basis, will be approximately $4.1 million. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and the government. These statements include, but are not limited to, statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering, the anticipated use of proceeds therefrom, the exercise of the Series Warrants prior to their expiration, the Companys operations and business strategy, and the Companys expected financial results. The forward-looking statements contained in this press release are based on managements current expectations and are subject to substantial risks, uncertainty, changes in circumstances and market and other conditions. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.For Investor or Media Inquiries: Syra Health IR/PR and Marketing Director Christine Drury 317-385-9227